Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus (SARS-CoV-2) that can progress to severe multiorgan disease requiring hospitalization. The medium and long-term impact in survivors of COVID-19 on lung function, imaging by thoracic CT, exercise capacity, and health-related quality of life and the relation of these parameters remains to be determined.
Description: in ml
Measure: Forced vital capacity (FVC) Time: at 6-12 months after dischargeDescription: DLCO (%predicted); DLCO/alveolar volume- DLCO/VA (%predicted)
Measure: Lung diffusion capacity for carbon monoxide (DLCO) Time: at 6-12 months after dischargeDescription: m
Measure: 6-minute walk test distance Time: at 6-12 months after dischargeDescription: scores range between 0 and 100 with higher scores indicating a better HRQoL
Measure: Short-form 36 questionnaire (SF-36) Time: at 6-12 months after dischargeDescription: from incremental Cardiopulmonary exercise test (% of predicted)
Measure: Oxygen uptake at peak exercise Time: at 6-12 months after dischargeDescription: from incremental Cardiopulmonary exercise test (L/L)
Measure: Minute-ventilation/carbon dioxide output during exercise Time: at 6-12 months after dischargeDescription: from incremental Cardiopulmonary exercise test (measured with 10-point categorical Borg scale
Measure: Dyspnea during exercise Time: at 6-12 months after dischargeDescription: lung parenchymal abnormalities as percentage of occupied lung
Measure: Thoracic CT findings Time: in hospital and at 6-12 months after dischargeDescription: in ml and %predicted
Measure: Forced expiratory volume in 1 second Time: at 6-12 months after dischargeDescription: in %
Measure: FEV1/FVC ratio Time: at 6-12 months after dischargeDescription: in %
Measure: Forced vital capacity %predicted (FVC%) Time: at 6-12 months after dischargeDescription: Recorded separately as present or absent) mortality (recorded as present or absent)
Measure: Signs and symptoms Time: in hospital and at 6-12 months after dischargeDescription: in days
Measure: Time to hospital discharge Time: in hospitalDescription: in days
Measure: ICU discharge Time: in hospitalDescription: in days
Measure: Weaning from intubation Time: in hospitalDescription: in days
Measure: Weaning from supplemental oxygen Time: in hospitalDescription: in days
Measure: Weaning from noninvasive mechanical ventilation Time: in hospitalDescription: recorded as present or absent
Measure: Mortality Time: in hospital and at 6-12 months after dischargeAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports